Management & Regulatory

What if a rare and deadly form of lung cancer, long considered a near-hopeless battle, suddenly had a new weapon in its fight? Picture a patient, grappling with the weight of a diagnosis of HER2-mutant non-small cell lung cancer (NSCLC), now finding a glimmer of possibility with an oral therapy

Imagine a political landscape where access to health care hinges on the drawing of district lines, a scenario unfolding right now as advocacy groups and lawmakers clash over congressional maps in a heated battle for influence. With reproductive rights and health funding under threat from

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent European Commission approval of Cabometyx for advanced

Imagine a world where thousands of Americans, including children, face the grim reality of kidney failure within a decade due to rare, debilitating conditions like C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These diseases, affecting around

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent FDA approval of Gilead Sciences’ Biktarvy for expanded HIV

Imagine living with a condition where even a small bite of protein-rich food could lead to severe neurological damage, a daily reality for thousands of individuals in the U.S. diagnosed with phenylketonuria (PKU), a rare genetic metabolic disorder. Affecting approximately one in every 13,500 to